Appendix B: Acronyms
| Acronym | Term |
|---|---|
| °C | degrees Celsius |
| °F | degrees Fahrenheit |
| % v | volume |
| 25-OH-vitamin D | 25-hydroxy vitamin D |
| AE | adverse effect |
| AHR | adjusted hazard ratio |
| ALT | alanine aminotransferase |
| ANC | absolute neutrophil count |
| app | mobile application |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| ASCVD | atherosclerotic cardiovascular disease |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| AUC0-12h | area under the curve at 12 hours post-dose |
| AUC24h | area under the curve at 24 hours post-dose |
| AUCtau | area under the curve |
| AV | atrioventricular |
| BCRP | breast cancer resistance protein |
| BHIVA | British HIV Association |
| BMD | bone mineral density |
| BMI | body mass index |
| BSA | body surface area |
| C0h | pre-dose concentration |
| C12h | concentration at 12 hours |
| C24h | concentration at 24 hours |
| CAR | chimeric antigen receptor |
| Cavg | average plasma concentration |
| CBC | complete blood count |
| CD4 | CD4 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CI | confidence interval |
| CK | creatine kinase |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CMV | cytomegalovirus |
| CNS | central nervous system |
| Cr | creatinine |
| CrCl | creatinine clearance |
| CT | continuous therapy |
| Ctau | concentration at the end of a dosing interval |
| Ctrough | trough concentration |
| CTx | C-telopeptide of type 1 collagen |
| CV | coefficients of variation |
| CVDI | cardiovascular disease |
| CYP | cytochrome P |
| CYPB26 | cytochrome P450 family 2 subfamily B member 6 |
| DAIDS | Division of AIDS (NIAID) |
| DBS | dried blood spot |
| dL | deciliter |
| DM | diabetes mellitus |
| DNA | deoxyribonucleic acid |
| DOT | directly observed therapy |
| DRESS | drug reaction (or rash) with eosinophilia and systemic symptoms |
| DSG | delayed switch group |
| DSMB | Data Safety Monitoring Board |
| DT | dispersible tablet |
| DXA | dual energy x-ray absorptiometry |
| E2D2 | Every Dose, Every Day [Toolkit and App] |
| EBV | Epstein-Barr virus |
| EC | enteric-coated |
| EC50 | half maximal effective concentration |
| ECG | electrocardiogram |
| EEG | electroencephalogram |
| eGFR | estimated glomerular filtration rate |
| EM | erythema multiforme or extensive metabolizers |
| FCT | film-coated tablet |
| FDA | Food and Drug Administration |
| FDC | fixed-dose combination |
| fL | femtoliter |
| FLP | fasting lipid profile |
| fmol | femtomole |
| FPG | fasting plasma glucose |
| g | gram |
| g/dL | grams per deciliter |
| G6PD | glucose-6-phosphate dehydrogenase |
| GA | gestational age |
| GFR | glomerular filtration rate |
| GI | gastrointestinal |
| GLSM | geometric least squares mean |
| GM | geometric mean |
| GMR | geometric mean ratio |
| gp | glycoprotein |
| gp120 | glycoprotein 120 |
| h | hour |
| HA | height age |
| HAV | hepatitis A virus |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HD | high dose |
| HDL-C | high-density lipoprotein cholesterol |
| Hgb | hemoglobin |
| HgbA1c | glycosylated hemoglobin |
| HHS | Department of Health and Human Services |
| HIV RNA or HIV-1 RNA | viral load |
| HLA | human leukocyte antigen |
| HRSA | Health Resources and Services Administration |
| HSR | hypersensitivity reaction |
| HSV | herpes simplex virus |
| IAS-USA | International Antiviral Society-USA |
| IFPG | impaired fasting plasma glucose |
| IGT | impaired glucose tolerance |
| IM | intramuscular |
| INSTI | integrase strand transfer inhibitor |
| IQ | inhibitory quotient |
| IQR | interquartile range |
| IR | insulin resistance |
| IRIS | immune reconstitution inflammatory syndrome |
| ISG | immediate switch group |
| IU | international units |
| IV | intravenous |
| IVIG | intravenous immune globulin |
| kg | kilogram |
| L | liter |
| LAI | long-acting injectable |
| LBW | low birth weight |
| LDL | low-density lipoprotein |
| LDL-C | low-density lipoprotein cholesterol |
| LFT | liver function test |
| Log10 | the logarithm to the base 10 |
| LS | lipodystrophy syndrome |
| LVH | left ventricular hypertrophy |
| m2 | square meter |
| mcg | microgram |
| MCV | mean cell volume |
| mDAART | modified directly administered ART |
| MEMS | Medication Event Monitoring System |
| mg | milligram |
| min | minute |
| mL | milliliter |
| mm | millimeter |
| mm3 | cubic millimeter |
| mmol | millimole |
| N/A | not available or not applicable |
| NASBA | nucleic acid sequence-based amplification |
| NAT | nucleic acid test |
| ng | nanogram |
| NHLBI | National Heart, Lung, and Blood Institute |
| NIH | National Institutes of Health |
| nM | nanometer |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRTI | nucleoside reverse transcriptase inhibitor |
| NTD | neural tube defect |
| OARAC | Office of AIDS Research Advisory Council |
| OAT | organic anion transporter |
| OATP | organic anion transporter polypeptide |
| OBT | optimized background therapy |
| OGTT | oral glucose tolerance test |
| OI | opportunistic infection |
| oz | ounce |
| PA-IC95 | protein-adjusted IC95 |
| The Panel | the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV |
| PBMC | peripheral blood mononuclear cell |
| PCP | Pneumocystis jirovecii pneumonia |
| PCR | polymerase chain reaction |
| PEP | post-exposure prophylaxis |
| PG | plasma glucose |
| P-gp | P-glycoprotein |
| PI | protease inhibitor |
| PK | pharmacokinetic |
| POC | point of care |
| PPI | proton pump inhibitor |
| PrEP | pre-exposure prophylaxis |
| PUFA | polyunsaturated fatty acid |
| py | patient years |
| QTc | corrected QT |
| RCT | randomized controlled trial |
| RNA | ribonucleic acid |
| RPG | random plasma glucose |
| RR | relative risk |
| RT-PCR | reverse transcription polymerase chain reaction |
| SAM | severe acute malnutrition |
| SCT | short-cycle therapy |
| SD | standard deviation |
| SJS | Stevens-Johnson syndrome |
| SM | slow metabolizers |
| SMR | sexual maturity rating |
| SMS | short message service |
| SOC | standard of care |
| SQ | subcutaneous |
| STI | sexually transmitted infection |
| STR | single-tablet regimen |
| T½ | half-life |
| TB | tuberculosis |
| TBLH | total body less head |
| TC | total cholesterol |
| TDM | therapeutic drug monitoring |
| TEN | toxic epidermal necrolysis |
| TG | triglyceride |
| TMA | transcription-mediated amplification |
| Tmax | time to reach maximum concentration |
| U=U | Undetectable = Untransmittable |
| UGT | uridine diphosphate glucuronosyltransferase |
| UGT1A | uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex |
| ULN | upper limit of normal |
| v/v | volume per volume |
| w | weight |
| WHO | World Health Organization |
| XR | extended release |
Appendix B: Acronyms
| Acronym | Term |
|---|---|
| °C | degrees Celsius |
| °F | degrees Fahrenheit |
| % v | volume |
| 25-OH-vitamin D | 25-hydroxy vitamin D |
| AE | adverse effect |
| AHR | adjusted hazard ratio |
| ALT | alanine aminotransferase |
| ANC | absolute neutrophil count |
| app | mobile application |
| ART | antiretroviral therapy |
| ARV | antiretroviral |
| ASCVD | atherosclerotic cardiovascular disease |
| AST | aspartate aminotransferase |
| AUC | area under the curve |
| AUC0-12h | area under the curve at 12 hours post-dose |
| AUC24h | area under the curve at 24 hours post-dose |
| AUCtau | area under the curve |
| AV | atrioventricular |
| BCRP | breast cancer resistance protein |
| BHIVA | British HIV Association |
| BMD | bone mineral density |
| BMI | body mass index |
| BSA | body surface area |
| C0h | pre-dose concentration |
| C12h | concentration at 12 hours |
| C24h | concentration at 24 hours |
| CAR | chimeric antigen receptor |
| Cavg | average plasma concentration |
| CBC | complete blood count |
| CD4 | CD4 T lymphocyte |
| CDC | Centers for Disease Control and Prevention |
| CI | confidence interval |
| CK | creatine kinase |
| Cmax | maximum plasma concentration |
| Cmin | minimum plasma concentration |
| CMV | cytomegalovirus |
| CNS | central nervous system |
| Cr | creatinine |
| CrCl | creatinine clearance |
| CT | continuous therapy |
| Ctau | concentration at the end of a dosing interval |
| Ctrough | trough concentration |
| CTx | C-telopeptide of type 1 collagen |
| CV | coefficients of variation |
| CVDI | cardiovascular disease |
| CYP | cytochrome P |
| CYPB26 | cytochrome P450 family 2 subfamily B member 6 |
| DAIDS | Division of AIDS (NIAID) |
| DBS | dried blood spot |
| dL | deciliter |
| DM | diabetes mellitus |
| DNA | deoxyribonucleic acid |
| DOT | directly observed therapy |
| DRESS | drug reaction (or rash) with eosinophilia and systemic symptoms |
| DSG | delayed switch group |
| DSMB | Data Safety Monitoring Board |
| DT | dispersible tablet |
| DXA | dual energy x-ray absorptiometry |
| E2D2 | Every Dose, Every Day [Toolkit and App] |
| EBV | Epstein-Barr virus |
| EC | enteric-coated |
| EC50 | half maximal effective concentration |
| ECG | electrocardiogram |
| EEG | electroencephalogram |
| eGFR | estimated glomerular filtration rate |
| EM | erythema multiforme or extensive metabolizers |
| FCT | film-coated tablet |
| FDA | Food and Drug Administration |
| FDC | fixed-dose combination |
| fL | femtoliter |
| FLP | fasting lipid profile |
| fmol | femtomole |
| FPG | fasting plasma glucose |
| g | gram |
| g/dL | grams per deciliter |
| G6PD | glucose-6-phosphate dehydrogenase |
| GA | gestational age |
| GFR | glomerular filtration rate |
| GI | gastrointestinal |
| GLSM | geometric least squares mean |
| GM | geometric mean |
| GMR | geometric mean ratio |
| gp | glycoprotein |
| gp120 | glycoprotein 120 |
| h | hour |
| HA | height age |
| HAV | hepatitis A virus |
| HBV | hepatitis B virus |
| HCV | hepatitis C virus |
| HD | high dose |
| HDL-C | high-density lipoprotein cholesterol |
| Hgb | hemoglobin |
| HgbA1c | glycosylated hemoglobin |
| HHS | Department of Health and Human Services |
| HIV RNA or HIV-1 RNA | viral load |
| HLA | human leukocyte antigen |
| HRSA | Health Resources and Services Administration |
| HSR | hypersensitivity reaction |
| HSV | herpes simplex virus |
| IAS-USA | International Antiviral Society-USA |
| IFPG | impaired fasting plasma glucose |
| IGT | impaired glucose tolerance |
| IM | intramuscular |
| INSTI | integrase strand transfer inhibitor |
| IQ | inhibitory quotient |
| IQR | interquartile range |
| IR | insulin resistance |
| IRIS | immune reconstitution inflammatory syndrome |
| ISG | immediate switch group |
| IU | international units |
| IV | intravenous |
| IVIG | intravenous immune globulin |
| kg | kilogram |
| L | liter |
| LAI | long-acting injectable |
| LBW | low birth weight |
| LDL | low-density lipoprotein |
| LDL-C | low-density lipoprotein cholesterol |
| LFT | liver function test |
| Log10 | the logarithm to the base 10 |
| LS | lipodystrophy syndrome |
| LVH | left ventricular hypertrophy |
| m2 | square meter |
| mcg | microgram |
| MCV | mean cell volume |
| mDAART | modified directly administered ART |
| MEMS | Medication Event Monitoring System |
| mg | milligram |
| min | minute |
| mL | milliliter |
| mm | millimeter |
| mm3 | cubic millimeter |
| mmol | millimole |
| N/A | not available or not applicable |
| NASBA | nucleic acid sequence-based amplification |
| NAT | nucleic acid test |
| ng | nanogram |
| NHLBI | National Heart, Lung, and Blood Institute |
| NIH | National Institutes of Health |
| nM | nanometer |
| NNRTI | non-nucleoside reverse transcriptase inhibitor |
| NRTI | nucleoside reverse transcriptase inhibitor |
| NTD | neural tube defect |
| OARAC | Office of AIDS Research Advisory Council |
| OAT | organic anion transporter |
| OATP | organic anion transporter polypeptide |
| OBT | optimized background therapy |
| OGTT | oral glucose tolerance test |
| OI | opportunistic infection |
| oz | ounce |
| PA-IC95 | protein-adjusted IC95 |
| The Panel | the Panel on Antiretroviral Therapy and Medical Management of Children Living With HIV |
| PBMC | peripheral blood mononuclear cell |
| PCP | Pneumocystis jirovecii pneumonia |
| PCR | polymerase chain reaction |
| PEP | post-exposure prophylaxis |
| PG | plasma glucose |
| P-gp | P-glycoprotein |
| PI | protease inhibitor |
| PK | pharmacokinetic |
| POC | point of care |
| PPI | proton pump inhibitor |
| PrEP | pre-exposure prophylaxis |
| PUFA | polyunsaturated fatty acid |
| py | patient years |
| QTc | corrected QT |
| RCT | randomized controlled trial |
| RNA | ribonucleic acid |
| RPG | random plasma glucose |
| RR | relative risk |
| RT-PCR | reverse transcription polymerase chain reaction |
| SAM | severe acute malnutrition |
| SCT | short-cycle therapy |
| SD | standard deviation |
| SJS | Stevens-Johnson syndrome |
| SM | slow metabolizers |
| SMR | sexual maturity rating |
| SMS | short message service |
| SOC | standard of care |
| SQ | subcutaneous |
| STI | sexually transmitted infection |
| STR | single-tablet regimen |
| T½ | half-life |
| TB | tuberculosis |
| TBLH | total body less head |
| TC | total cholesterol |
| TDM | therapeutic drug monitoring |
| TEN | toxic epidermal necrolysis |
| TG | triglyceride |
| TMA | transcription-mediated amplification |
| Tmax | time to reach maximum concentration |
| U=U | Undetectable = Untransmittable |
| UGT | uridine diphosphate glucuronosyltransferase |
| UGT1A | uridine diphosphate (UDP)-glucuronosyltransferase family 1 member A complex |
| ULN | upper limit of normal |
| v/v | volume per volume |
| w | weight |
| WHO | World Health Organization |
| XR | extended release |
Download Guidelines
- Section Only PDF (106.19 KB)
- Full Guideline PDF (6.83 MB)
- Recommendations Only PDF (871.2 KB)
- Tables Only PDF (1.43 MB)
- Drug Tables Only PDF (2.57 MB)